Adam Boudjemai

Adam Boudjemai is a Vice President at Interlock Equity, a Los Angeles– and Chicago-based private equity firm founded in 2021 that partners with founders and management teams of "knowledge economy" and people-based businesses in the lower middle market. He concentrates on investments in business and healthcare services companies, focusing on sourcing, diligence, and value creation within the firm's portfolio.

Before Interlock, Adam spent several years at Shore Capital Partners, the Chicago-based microcap private equity firm that partners with companies generally in the $1–10 million EBITDA range. He joined Shore as an Analyst and rose to Senior Associate, where he was responsible for conducting due diligence on new investment opportunities and implementing value-creation initiatives across portfolio companies. During that time he also supported Shore's real estate platform alongside Steve Malley. His email and phone in the known stub data ([hidden] / 312-348-7580) trace to this Shore Capital tenure.

Adam began his career in investment banking as an analyst in the healthcare group of P&M Corporate Finance (PMCF), the Chicago-based investment banking affiliate of Plante Moran, where he advised healthcare companies on M&A with a specific focus on medical devices.

He earned a B.A. in Finance, cum laude, with a minor in French, from the Eli Broad College of Business at Michigan State University (2012–2016).

• Invests through Interlock Equity in founder-led, people-based B2B and healthcare services businesses — the "knowledge economy," where value is driven by talent rather than physical assets.
• Sector lens spans professional/tech-enabled staffing, strategy and management consulting, life sciences services, digital and marketing services, and healthcare services.
• Transaction types are control buyouts and growth investments in the lower middle market, typically partnering with founders and management teams for operational scaling and buy-and-build (Interlock's inaugural fund closed oversubscribed at $390 million in 2023).
• Firm positioning: "focused exclusively on partnering with founders of people-based businesses providing mission-critical B2B and healthcare services." Adam's personal remit is squarely in business and healthcare services deal execution and value creation.
• His earlier PE experience at Shore Capital centered on microcap ($1–10M EBITDA) platform-building, giving him a background in serial add-on acquisitions and management partnerships.